Quidel to Hold Third Quarter 2018 Financial Results Conference Call on November 6th, 2018

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic
testing solutions, cellular-based virology assays and molecular
diagnostic systems, will report third quarter 2018 financial results
after market close on Tuesday, November 6, 2018.

Following the release of results, Douglas Bryant, president and chief
executive officer, and Randy Steward, chief financial officer, will host
an investment community conference call beginning at 5:00 p.m. Eastern
Time (2:00 p.m. Pacific Time) to discuss the results and answer
questions. During the conference call, the company will also discuss
business and financial developments and trends. The companya??s statements
may contain or constitute material information that has not been
previously disclosed.

To participate in the live call by telephone from the U.S., dial
877-930-5791, or from outside the U.S., dial 253-336-7286, and enter the
audience pass code 802-9037.

A live webcast of the call can be accessed on the Investor Relations
section of the Quidel website (
The website replay will be available for 14 days. The telephone replay
will be available for 48 hours beginning at 8:00 p.m. Eastern Time (5:00
p.m. Pacific Time) on November 6, 2018 by dialing 855-859-2056 from the
U.S., or by dialing 404-537-3406 for international callers, and entering
pass code 802-9037.

About Quidel Corporation

Quidel Corporation serves to enhance the health and well-being of people
around the globe through the development of diagnostic solutions that
can lead to improved patient outcomes and provide economic benefits to
the healthcare system. Marketed under the SofiaA, QuickVueA, D3A Direct
Detection, ThyretainA, TriageA and InflammaDryA leading brand names, as
well as under the new SolanaA, AmpliVueA and LyraA molecular diagnostic
brands, Quidela??s products aid in the detection and diagnosis of many
critical diseases and conditions, including, among others, influenza,
respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease
and fecal occult blood. Quidela??s recently acquired TriageA system of
tests comprises a comprehensive test menu that provides rapid,
cost-effective treatment decisions at the point-of-care (POC), offering
a diverse immunoassay menu in a variety of tests to provide healthcare
providers with diagnostic answers for quantitative BNP, CK-MB, d-dimer,
myoglobin, troponin I and qualitative TOX Drug Screen. Quidela??s research
and development engine is also developing a continuum of diagnostic
solutions from advanced immunoassay to molecular diagnostic tests to
further improve the quality of healthcare in physiciansa?? offices and
hospital and reference laboratories. For more information about Quidela??s
comprehensive product portfolio, visit

Quidel to Hold Third Quarter 2018 Financial Results Conference Call on November 6th, 2018
View source version on
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«     2020    »